These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7576008)

  • 1. Platelet binding characteristics distinguish placebo responders from nonresponders in depression.
    Sheline YI; Black KJ; Bardgett ME; Csernansky JG
    Neuropsychopharmacology; 1995 Jul; 12(4):315-22. PubMed ID: 7576008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors.
    Hrdina PD; Bakish D; Chudzik J; Ravindran A; Lapierre YD
    J Psychiatry Neurosci; 1995 Jan; 20(1):11-9. PubMed ID: 7865496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet serotonin markers and depressive symptomatology.
    Sheline YI; Bardgett ME; Jackson JL; Newcomer JW; Csernansky JG
    Biol Psychiatry; 1995 Apr; 37(7):442-7. PubMed ID: 7786957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients.
    Arora RC; Meltzer HY
    Life Sci; 1989; 44(11):725-34. PubMed ID: 2927243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet serotonin-2 receptor binding sites in depression and suicide.
    Pandey GN; Pandey SC; Janicak PG; Marks RC; Davis JM
    Biol Psychiatry; 1990 Aug; 28(3):215-22. PubMed ID: 2378926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine versus placebo: a double-blind comparison in depressed patients.
    Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
    J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression.
    Rickels K; Amsterdam J; Clary C; Fox I; Schweizer E; Weise C
    J Clin Psychiatry; 1992 Feb; 53 Suppl():30-2. PubMed ID: 1531820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?
    Castrogiovanni P; Blardi P; De Lalla A; Dell'Erba A; Auteri A
    Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine.
    Ko HC; Lu RB; Shiah IS; Hwang CC
    Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
    Kiev A
    J Clin Psychiatry; 1992 Feb; 53 Suppl():27-9. PubMed ID: 1531818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
    Fabre LF
    J Clin Psychiatry; 1992 Feb; 53 Suppl():40-3. PubMed ID: 1531823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet serotonin levels support depression scores for women with postpartum depression.
    Maurer-Spurej E; Pittendreigh C; Misri S
    J Psychiatry Neurosci; 2007 Jan; 32(1):23-9. PubMed ID: 17245471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients.
    Claghorn JL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():33-5. PubMed ID: 1531821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome.
    Karege F; Widmer J; Bovier P; Gaillard JM
    Neuropsychopharmacology; 1994 May; 10(3):207-14. PubMed ID: 7916918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of placebo responders and nonresponders in subgroups of depressive disorder.
    Bialik RJ; Ravindran AV; Bakish D; Lapierre YD
    J Psychiatry Neurosci; 1995 Jul; 20(4):265-70. PubMed ID: 7647079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine in the treatment of depression: a comparison with imipramine and placebo.
    Feighner JP; Boyer WF
    J Clin Psychiatry; 1992 Feb; 53 Suppl():44-7. PubMed ID: 1531824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?
    Evans KR; Sills T; Wunderlich GR; McDonald HP
    J Psychiatr Res; 2004; 38(4):437-44. PubMed ID: 15203296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet 3H-imipramine binding and response to minaprine in patients with major depression.
    Maj M; Mastronardi P; Palomba U; Romano M; Ventra C; Kemali D
    Pharmacopsychiatry; 1988 Mar; 21(2):101-3. PubMed ID: 3393597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet serotonergic markers and Tridimensional Personality Questionnaire measures in a clinical sample.
    Nelson EC; Cloninger CR; Przybeck TR; Csernansky JG
    Biol Psychiatry; 1996 Aug; 40(4):271-8. PubMed ID: 8871773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which depressions respond to placebo?
    Fairchild CJ; Rush AJ; Vasavada N; Giles DE; Khatami M
    Psychiatry Res; 1986 Jul; 18(3):217-26. PubMed ID: 3529150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.